Dx&Vx

2023
07Launch of the global market for 'Formulamate-Ofmom', a probiotic for babies
Dx&Vx BJ (Beijing DIWAYSE Co., Ltd.), the world's largest (37 trillion won in revenue) Chinese antibiotic market, launches two of its own brand antibiotics
(Dx&Vx Azithromycin For Suspension / Tablets)
06 Selected for National R&D Project for technology development for the diagnosis of adult diseases
(National Convergence Technology Project for Semiconductors and Biosciences)
04
The decision to acquire 63% stake in Evixgen Co., Ltd.
03 Resumption of sovereign trading
02 Establishment of Beijing DIWAYSE Co., Ltd. (Beijing corporation)

2022
12
59th Trade Day, awarded "Top Exporter with $3 million"
10 Acquisition of Korea Bio-Pharm Co., Ltd.
Establishment of Microbiome Research Institute
Obtained license for pharmaceutical wholesale business (KGSP)
Raised 17 billion won through convertible bonds (CB)
09 Raised 17.8 billion won through convertible bonds (CB)
07 Signed MOU with China Europe International Foundation for Medical Equipment for medical device development, supply, and sales
04 Selected for a government project to build an AI-based mRNA vaccine platform (with Hanyang University)
03 Signed MOU with Hanyang Life Science Technology Institute for next-generation mRNA vaccine development
01 Applied for patent for AI-based genome analysis platform

2011~2020
2019 Obtained Grade A in Molecular Cytogenetics (NGS, CMA) from the Korea Genetic Testing Evaluation Institute
2018 Merged with Oxford Vacmedix UK Limited as a subsidiary
2017 Changed name to CanCerLab Co., Ltd.
Started Genome Check M service (Non-invasive prenatal genetic testing, formerly known as TheMomsCanning)
2015 Listed on KOSDAQ (Korea Exchange)
2014 Listed on KONEX (Korea Exchange)
2012 ISO 13485 certification and Venture Company certification
2011 Started Genome Check P service

2001~2010
2009 Commencement of Genome Check G service (Newborn and Pediatric Genome Test, (Former) G-Scanning)
2008 Acquisition of Gene Testing Institution Certification (Korea Centers for Disease Control and Prevention)
2007 Establishment of Molecular Genetics Institute at MG Med Co., Ltd.
Commencement of Genome Check K service (Fetal Genome Test, (Former) MG-test)
Development of MSP kit for Diagnosing Fragile X Syndrome (Intellectual Disability)
2006 Development of PCR kit for Diagnosing Achondroplasia (Dwarfism)
Development of STD Diagnostic PCR Kit and HPV Genotyping Kit
2001 Establishment of MG Med Co., Ltd.